GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (OTCPK:CASBF) » Definitions » Purchase Of Investment

CASBF (CanSino Biologics) Purchase Of Investment : $-1,377.15 Mil (TTM As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is CanSino Biologics Purchase Of Investment?

CanSino Biologics's purchase of investment for the three months ended in Jun. 2024 was $-467.22 Mil. It means CanSino Biologics spent $467.22 Mil on purchasing investments. CanSino Biologics's purchase of investment for the trailing twelve months (TTM) ended in Jun. 2024 was $-1,377.15 Mil.

Compared with last quarter ($-298.47 Mil in Mar. 2024 ), CanSino Biologics spent more money on purchasing investments in Jun. 2024 ($-467.22 Mil).

CanSino Biologics Purchase Of Investment Historical Data

The historical data trend for CanSino Biologics's Purchase Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanSino Biologics Purchase Of Investment Chart

CanSino Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Purchase Of Investment
Get a 7-Day Free Trial -237.34 -961.42 -1,331.24 -1,773.10 -1,133.70

CanSino Biologics Quarterly Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Purchase Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -217.13 -215.34 -396.12 -298.47 -467.22

CanSino Biologics Purchase Of Investment Calculation

Purchase of Investments represents cash outflow on the purchase of investments in securities.

Purchase Of Investment for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1,377.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CanSino Biologics Purchase Of Investment Related Terms

Thank you for viewing the detailed overview of CanSino Biologics's Purchase Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

CanSino Biologics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (OTCPK:CASBF) » Definitions » Purchase Of Investment
Comparable Companies
HKSE:00570 HKSE:02005 HKSE:01558 HKSE:02186 HKSE:02877 HKSE:03613 HKSE:00512 HKSE:02096 HKSE:01681 HKSE:01349 ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN TSE:4502 XSWX:GALD XTAE:TEVA NSE:DIVISLAB XSWX:SDZ VTRS
Traded in Other Exchanges
06185:Hong Kong CJH:Germany 688185:China
Address
185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN
Website
https://www.cansinotech.com
CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. Its products are Menhycia and Menphecia; Convidecia, Convidecia Air, and XBB.1.5 Variant; Ad5-EBOV; PCV13i; PBPV; and DTcP Infant. Its geographic areas are PRC and Overseas. It generates the majority of its revenue from the PRC.